Pierre-Fabre fails to provide enough clinical evidence to convince NICE about Javlor
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, says that it will not, for the time being, be recommending Pierre-Fabre's vinca alkaloid anticancer, Javlor (vinflunine), as a second-line treatment for bladder cancer because there is not enough evidence to show that the drug is clinically effective.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.